

Aspruzyo Sprinkle[™] (ranolazine) – New drug approval

- On February 28, 2022, the <u>FDA approved</u> Sun Pharma's <u>Aspruzyo Sprinkle (ranolazine)</u>, for the treatment of chronic angina.
 - Aspruzyo Sprinkle may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers.
- Aspruzyo Sprinkle is an extended-release granule formulation of ranolazine. Ranolazine is currently available generically as an extended-release <u>tablet</u>. The tablet formulation shares the same indication as Aspruzyo Sprinkle.
- Aspruzyo Sprinkle is contraindicated in patients:
 - Taking strong inhibitors of CYP3A
 - Taking inducers of CYP3A
 - With liver cirrhosis.
- Warnings and precautions for Aspruzyo Sprinkle include QT interval prolongation and renal failure.
- The most common adverse reactions (> 4% and more common than with placebo) with Aspruzyo Sprinkle use were dizziness, headache, constipation, and nausea.
- The recommended initial dose of Aspruzyo Sprinkle is 500 mg orally twice daily and increased to 1000 mg orally twice daily, as needed, based on clinical symptoms.
 - The maximum recommended daily dose of Aspruzyo Sprinkle is 1000 mg twice daily.
 - Aspruzyo Sprinkle can be administered with soft food (eg, apple sauce and yogurt) or via nasogastric and gastric tube.
- Sun Pharma's launch plans for Aspruzyo Sprinkle are pending. Aspruzyo Sprinkle will be available as a 500 and 1000 mg extended-release granules.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.